Recently introduced thrombolytic therapy regimens have been sufficiently effective and safer in patients with prosthetic valve thrombosis

Abstract

To the Editor, We have read with great interest the article by Araiza-Garaygordobil et al. entitled “Thrombolytic treatment for acute prosthetic valve thrombosis: Is it better than surgery?” [1]. The authors reported a case of mitral prosthetic valve thrombosis (PVT), which was successfully treated with an intravenous bolus of 15 mg tissue type plasminogen activator (t-PA) and continuous infusion of 85 mg t-PA for 90 min. We congratulate the authors for achieving a successful outcome in such a high-risk patient. However, we would like to contribute to the case report discussing the new low-dose slow-infusion thrombolytic therapy (TT) regimens which have been associated with lower complication rates.